
Eli Lilly and Novo Nordisk Face Diverging Fortunes in the Booming GLP-1 Market
Eli Lilly and Novo Nordisk both beat Q2 estimates and raised outlooks, but Wall Street rewarded Lilly while punishing Novo over pipeline and market share concerns in the $100B+ obesity drug sector.


















